| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| RDY | Dr. Reddy's Laboratories Ltd | $35.7 | $5.93B | N/A |
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
http://www.zacks.com/stock/news/425808/biomarins-vimizim-wins-nod-in-china-for-rare-genetic-malady?cid=CS-ZC-FT-425808
Jun 06, 2019 - BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
0
Zynerba Releases Data on Epilepsy Candidate, Stock Down
http://www.zacks.com/stock/news/526215/zynerba-releases-data-on-epilepsy-candidate-stock-down?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526215
Sep 19, 2019 - Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
0
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
http://www.zacks.com/stock/news/532018/the-zacks-analyst-blog-highlights-dr-reddys-wns-and-azure-power?cid=CS-ZC-FT-press_releases-532018
Sep 23, 2019 - The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
0
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen
http://www.zacks.com/stock/news/543304/mylan-myl-to-pay-%2430m-to-settle-sec-charges-for-epipen?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-543304
Sep 30, 2019 - Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
0
New Strong Sell Stocks for November 11th
http://www.zacks.com/stock/news/614102/new-strong-sell-stocks-for-november-11th?cid=CS-ZC-FT-tale_of_the_tape|new_zacks_#5_rank_stocks-614102
Nov 11, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
0
New Strong Sell Stocks for November 13th
http://www.zacks.com/stock/news/617737/new-strong-sell-stocks-for-november-13th?cid=CS-ZC-FT-tale_of_the_tape|new_zacks_#5_rank_stocks-617737
Nov 13, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
0
New Strong Sell Stocks for November 15th
http://www.zacks.com/stock/news/621253/new-strong-sell-stocks-for-november-15th?cid=CS-ZC-FT-tale_of_the_tape|new_zacks_#5_rank_stocks-621253
Nov 15, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
0
Teva Reintroduces Generic Depo-Provera Injection in U.S.
http://www.zacks.com/stock/news/277080/teva-reintroduces-generic-depo-provera-injection-in-us?cid=CS-ZC-FT-277080
Sep 27, 2017 - Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.
0
VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down
http://www.zacks.com/stock/news/282370/vivus-vvus-q3-loss-narrows-qsymia-falters-shares-down?cid=CS-ZC-FT-282370
Nov 09, 2017 - VIVUS (VVUS) reported third-quarter results wherein it reported narrower-than- expected loss. However, Qsymia sales fell from the year-ago period.
0
Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y
http://www.zacks.com/stock/news/290129/dr-reddys-rdy-q3-earnings-fall-revenues-improve-y-y?cid=CS-ZC-FT-290129
Jan 25, 2018 - Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
0